{"nctId":"NCT00618774","briefTitle":"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination","startDateStruct":{"date":"2008-01"},"conditions":["Hypertension"],"count":259,"armGroups":[],"interventions":[{"name":"telmisartan40/amlodipine5","otherNames":[]},{"name":"telmisartan80/amlodipine5","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients with essential hypertension\n2. Outpatient\n\nExclusion Criteria:\n\n* Patients whose SBP \\>=180 mmHg or DBP \\>=110 mmHg at the end of treatment visit of the double-blind treatment period in the \"non-responder trials\"\n* Patients who have met any of the exclusion criteria defined in the \"non-responder trials\"","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experienced Adverse Events","description":"An adverse event is defined as any untoward medical occurrence","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null},{"groupId":"OG001","value":"77.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Seated Diastolic Blood Pressure at Week 8","description":"mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.81","spread":"6.65"},{"groupId":"OG001","value":"15.75","spread":"6.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Seated Systolic Blood Pressure at Week 8","description":"mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.89","spread":"12.2"},{"groupId":"OG001","value":"26.44","spread":"11.68"}]}]}]},{"type":"SECONDARY","title":"Seated DBP Control Rate at Trough After 8 Weeks","description":"Percentage of patients whose DBP \\<90 mmHg after 8 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null},{"groupId":"OG001","value":"52.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated SBP Control Rate at Trough After 8 Weeks","description":"Percentage of patients whose SBP \\<140 mmHg after 8 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Seated Diastolic Blood Pressure","description":"Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.67","spread":"7.16"},{"groupId":"OG001","value":"16.36","spread":"5.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.39","spread":"6.6"},{"groupId":"OG001","value":"17.78","spread":"7.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Seated Systolic Blood Pressure","description":"mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.73","spread":"12.55"},{"groupId":"OG001","value":"27.18","spread":"11.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.97","spread":"11.75"},{"groupId":"OG001","value":"28.11","spread":"12.78"}]}]}]},{"type":"SECONDARY","title":"Seated DBP Control Rate at Trough After 6 and 12 Months","description":"Percentage of patients whose DBP \\<90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null},{"groupId":"OG001","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated SBP Control Rate at Trough After 6 and 12 Months","description":"Percentage of patients whose SBP \\<140 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated DBP Response Rate at Trough","description":"Percentage of patients whose DBP \\<90 mmHg or decreased from pseudo-baseline by \\>=10 mmHg at 6 months and 12 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated SBP Response Rate at Trough","description":"Percentage of patients whose SBP \\<140 mmHg or decreased deom pseudo-baseline by \\>=20 mmHg after 6 and 12 months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Seated Blood Pressure Normalisation at Trough","description":"Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:\n\nOptimal: SBP \\<120 mmHg and DBP \\<80 mmHg\n\nNormal: SBP \\>=120 mmHg or DBP \\>=80 mmHg and SBP \\<130 mmHg or DBP \\<85 mmHg\n\nHigh normal: SBP \\>=130 mmHg or DBP \\>=85 mmHg and SBP \\<140 mmHg or DBP \\<90 mmHg\n\nNo: SBP \\>=140 mmHg or DBP \\>=90 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"39.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"35.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG","description":"Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":211},"commonTop":["Nasopharyngitis","Back pain","Dental caries"]}}}